ARC-IM Therapy To Support and Promote Recovery of Ambulatory Functions in People With Subacute and Chronic Spinal Cord Injury
Key facts
- Who runs it
- Ecole Polytechnique Fédérale de Lausanne
- Where
- Switzerland2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 12 people, planned
- Started
- Apr 2026
- Expected to end
- Apr 2032
- Type of study
- Interventional, 2 groups
- Treatments tested
- ARC-IM Therapy
- Record updated
- 21 April 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Must be at least 18 years old and no older than 65 years old at the time of enrollment
- Must be graded A, B, C, or D in the ASIA Impairment Scale (AIS)
- Must have a SCI level at T10 or higher as determined by ISNCSCI, with the region extending 6 cm above the tip of the conus remaining anatomically intact as determined by MRI
- Must have sustained their injury either less than 6 weeks prior to baseline (Group "Subacute SCI"), or more than 1 year prior to enrollment (Group "Chronic SCI")
- Must be suffering from a SCI due to trauma
- Must have a stable medical, physical and psychological condition as considered by the investigators and the delegated specialists
- Must have residual upper limb function to use the arms for weight bearing support (as determined by functional demonstration)
- Must be able to understand and interact with the study team in German, French or English
- Must agree to comply in good faith with all conditions of the study and to attend all scheduled appointments
- Must provide Informed Consent as documented by signature prior to any study-related procedures
- Must have an acceptable or highly effective method of contraception for women of childbearing capacity
Who cannot take part
- Must not have participated in another clinical study using drugs or medical devices within the 30 days preceding and during the present study
- Must not have previously been injected with stem cells in the spinal cord
- Must not have a history of epilepsy
- Must not have any diseases and conditions that would increase the morbidity and mortality of SCI surgery
- Must not have any existing contraindication to mobility functions (e.g., unhealed bone fractures, central nervous system disorder, peripheral nerve disorder, etc.)
- Must not suffer from SCI from other etiology than trauma (ischemic, tumoral, autoimmune, etc.)
- Must not have any other conditions that would make the subject unable to participate in testing in the judgment of the investigators (e.g., renal failure, hepatic dysfunction, cardiovascular disease, etc.)
- Must not be pregnant nor breastfeeding
- Must not have brain damage
- Must not require ventilator support
- Must not have any anatomical limitations in the implantation area as judged by the investigators (e.g., spinal stenosis, limiting protrusions, post-traumatic bone damage at area of implantation)
- Must not require the use of an intrathecal baclofen pump
- Must not have any active implanted devices
- Must not be the investigator him/herself, his/her family members, employees or other dependent persons
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The EIGER study aims to evaluate the safety and preliminary efficacy of ARC-IM Therapy (Epidural Electrical Stimulation) to support and promote recovery of ambulatory functions, such as walking, in people with subacute and chronic spinal cord injury.
The 2 groups in the trial
- Subacute SCITreatment being tested
Participants having sustained the injury less than 6 weeks prior to baseline (subacute). Participants will be provided with the ARC-IM Therapy.
Treatment: ARC-IM Therapy
- Chronic SCITreatment being tested
Participants having sustained the injury more than 1 year prior to enrollment (chronic). Participants will be provided with the ARC-IM Therapy.
Treatment: ARC-IM Therapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Fit questions
- Built from NCT07234903, who can take part
- Record updated
- 21 April 2026